Inflammatory Mediators of Cognitive Impairment in Bipolar Disorder

Overview

Journal J Psychiatr Res

Specialty Psychiatry

Date 2014 May 28

PMID 24862657

Citations 46

Authors

Isabelle E Bauer

Michaela C Pascoe

Bianca Wollenhaupt-Aguiar

Flavio Kapczinski

Jair C Soares

Affiliations

Soon will be listed here.

Abstract

Objectives: Recent studies have pointed to neuroinflammation, oxidative stress and neurotrophic factors as key mediators in the pathophysiology of mood disorders. Little is however known about the cascade of biological episodes underlying the cognitive deficits observed during the acute and euthymic phases of bipolar disorder (BD). The aim of this review is to assess the potential association between cognitive impairment and biomarkers of inflammation, oxidative stress and neurotrophic activity in BD.

Methods: Scopus (all databases), Pubmed and Ovid Medline were systematically searched with no language or year restrictions, up to November 2013, for human studies that collected both inflammatory markers and cognitive data in BD. Selected search terms were bipolar disorder, depression, mania, psychosis, inflammatory, cognitive and neurotrophic.

Results: Ten human studies satisfied the criteria for consideration. The findings showed that high levels of peripheral inflammatory-cytokine, oxidative stress and reduced brain derived neurotrophic factor (BDNF) levels were associated with poor cognitive performance. The BDNF val66met polymorphism is a potential vulnerability factor for cognitive impairment in BD.

Conclusions: Current data provide preliminary evidence of a link between the cognitive decline observed in BD and mechanisms of neuroinflammation and neuroprotection. The identification of BD specific inflammatory markers and polymorphisms in inflammatory response genes may be of assistance for therapeutic intervention.

Citing Articles

Pituitary adenylyl cyclase-activating polypeptide modulates the stress response: the involvement of different brain areas and microglia.

Singh A, Shim P, Naeem S, Rahman S, Lutfy K Front Psychiatry. 2025; 15:1495598.

PMID: 39931196 PMC: 11807976. DOI: 10.3389/fpsyt.2024.1495598.

Association between Sleep Quality and Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio in Patients with Bipolar Disorder.

Vaziri Harami R, Keyvanfar A, Semnani Y, Najafiarab H Med J Islam Repub Iran. 2024; 38:53.

PMID: 39416372 PMC: 11480673. DOI: 10.47176/mjiri.38.53.

Linking hearts and minds: understanding the cardiovascular impact of bipolar disorder.

Shah D, Singh B, Varnika F, Fredrick F, Meda A, Aggarwal K Future Cardiol. 2024; 20(13):709-718.

PMID: 39382013 PMC: 11552481. DOI: 10.1080/14796678.2024.2408944.

Mitophagy and cGAS-STING crosstalk in neuroinflammation.

Zhou X, Wang J, Yu L, Qiao G, Qin D, Law B Acta Pharm Sin B. 2024; 14(8):3327-3361.

PMID: 39220869 PMC: 11365416. DOI: 10.1016/j.apsb.2024.05.012.

Association among abnormal glycolipids, reproductive hormones, and cognitive dysfunction in female patients with bipolar disorder.

Zou T, Yang M, Chen Z, Xie H, Huang J, Qin Y BMC Psychiatry. 2024; 24(1):385.

PMID: 38773397 PMC: 11110249. DOI: 10.1186/s12888-024-05831-y.

References

Young A, Gallagher P, Watson S, Del-Estal D, Owen B, Ferrier I . Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology. 2004; 29(8):1538-45. DOI: 10.1038/sj.npp.1300471. View

Barbosa I, Huguet R, Sousa L, Abreu M, Rocha N, Bauer M . Circulating levels of GDNF in bipolar disorder. Neurosci Lett. 2011; 502(2):103-6. DOI: 10.1016/j.neulet.2011.07.031. View

Mattson M . Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol. 2001; 1(2):120-9. DOI: 10.1038/35040009. View

Rybakowski J, Borkowska A, Czerski P, Skibinska M, Hauser J . Polymorphism of the brain-derived neurotrophic factor gene and performance on a cognitive prefrontal test in bipolar patients. Bipolar Disord. 2003; 5(6):468-72. DOI: 10.1046/j.1399-5618.2003.00071.x. View

Quraishi S, Frangou S . Neuropsychology of bipolar disorder: a review. J Affect Disord. 2002; 72(3):209-26. DOI: 10.1016/s0165-0327(02)00091-5. View

Fernandes B, Gama C, Cereser K, Yatham L, Fries G, Colpo G . Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res. 2011; 45(8):995-1004. DOI: 10.1016/j.jpsychires.2011.03.002. View

Capuron L, Dantzer R . Cytokines and depression: the need for a new paradigm. Brain Behav Immun. 2003; 17 Suppl 1:S119-24. DOI: 10.1016/s0889-1591(02)00078-8. View

Murphy M . Mitochondrial dysfunction indirectly elevates ROS production by the endoplasmic reticulum. Cell Metab. 2013; 18(2):145-6. DOI: 10.1016/j.cmet.2013.07.006. View

Gimeno D, Kivimaki M, Brunner E, Elovainio M, De Vogli R, Steptoe A . Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study. Psychol Med. 2008; 39(3):413-23. PMC: 2788760. DOI: 10.1017/S0033291708003723. View

10.

Brambilla P, Harenski K, Nicoletti M, Mallinger A, Frank E, Kupfer D . Differential effects of age on brain gray matter in bipolar patients and healthy individuals. Neuropsychobiology. 2001; 43(4):242-7. DOI: 10.1159/000054897. View

11.

Ibrahim A, Kelly S, Adams C, Glazebrook C . A systematic review of studies of depression prevalence in university students. J Psychiatr Res. 2012; 47(3):391-400. DOI: 10.1016/j.jpsychires.2012.11.015. View

12.

Ancin I, Santos J, Teijeira C, Sanchez-Morla E, Bescos M, Argudo I . Sustained attention as a potential endophenotype for bipolar disorder. Acta Psychiatr Scand. 2010; 122(3):235-45. DOI: 10.1111/j.1600-0447.2009.01532.x. View

13.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

14.

Berk M, Conus P, Kapczinski F, Andreazza A, Yucel M, Wood S . From neuroprogression to neuroprotection: implications for clinical care. Med J Aust. 2010; 193(S4):S36-40. View

15.

Gigante A, Bond D, Lafer B, Lam R, Young L, Yatham L . Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: a meta-analysis. Bipolar Disord. 2012; 14(5):478-87. DOI: 10.1111/j.1399-5618.2012.01033.x. View

16.

Mackin P, Gallagher P, Watson S, Young A, Ferrier I . Changes in brain-derived neurotrophic factor following treatment with mifepristone in bipolar disorder and schizophrenia. Aust N Z J Psychiatry. 2007; 41(4):321-6. DOI: 10.1080/00048670701213211. View

17.

Boban M, Malojcic B, Mimica N, Vukovic S, Zrilic I . The frontal assessment battery in the differential diagnosis of dementia. J Geriatr Psychiatry Neurol. 2012; 25(4):201-7. DOI: 10.1177/0891988712464821. View

18.

Doganavsargil-Baysal O, Cinemre B, Aksoy U, Akbas H, Metin O, Fettahoglu C . Levels of TNF-α, soluble TNF receptors (sTNFR1, sTNFR2), and cognition in bipolar disorder. Hum Psychopharmacol. 2013; 28(2):160-7. DOI: 10.1002/hup.2301. View

19.

Frey B, Valvassori S, Reus G, Martins M, Petronilho F, Bardini K . Changes in antioxidant defense enzymes after d-amphetamine exposure: implications as an animal model of mania. Neurochem Res. 2006; 31(5):699-703. DOI: 10.1007/s11064-006-9070-6. View

20.

Strakowski S, Adler C, Almeida J, Altshuler L, Blumberg H, Chang K . The functional neuroanatomy of bipolar disorder: a consensus model. Bipolar Disord. 2012; 14(4):313-25. PMC: 3874804. DOI: 10.1111/j.1399-5618.2012.01022.x. View